Seborrhea - Pipeline Review, H2 2017

Global Markets Direct’s, ‘Seborrhea - Pipeline Review, H2 2017’, provides an overview of the Seborrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seborrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Seborrhea

The report reviews pipeline therapeutics for Seborrhea by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Seborrhea therapeutics and enlists all their major and minor projects

The report assesses Seborrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Seborrhea

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Seborrhea

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Seborrhea pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aclaris Therapeutics Inc

Amorepacific Corp

Biomar Microbial Technologies

EpiPharm AG

Vyome Biosciences Pvt Ltd

Aclaris Therapeutics Inc

Amorepacific Corp

Biomar Microbial Technologies

EpiPharm AG

Vyome Biosciences Pvt Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Seborrhea - Overview

Seborrhea - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Seborrhea - Overview

Seborrhea - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Seborrhea - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Seborrhea - Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Amorepacific Corp

Biomar Microbial Technologies

EpiPharm AG

Vyome Biosciences Pvt Ltd

Seborrhea - Drug Profiles

artemether - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydrogen peroxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-07A081 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-07A085 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketoconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAC-14028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Seborrhea - Dormant Projects

Seborrhea - Discontinued Products

Seborrhea - Product Development Milestones

Featured News & Press Releases

Aug 03, 2017: Aclaris Therapeutics Submits Marketing Authorization Application in Europe for A-101 40% Topical Solution as a Novel Treatment for Seborrheic Keratosis

Jun 13, 2017: Aclaris Therapeutics Announces Issuance of New US Patent For A-101 Topical Solutions

May 09, 2017: FDA Accepts Aclaris Therapeutics' New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition

Apr 26, 2017: Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution

Feb 27, 2017: Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis - a Common Skin Condition

Nov 15, 2016: Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition

Oct 19, 2016: New Observational Study Demonstrates Patient Impact of Seborrheic Keratosis, A Common, Undertreated Skin Condition Affecting 83.8 Million Americans

Jul 25, 2016: Aclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis; Provides Update on Clinical Programs

Jan 19, 2016: Aclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis

Mar 17, 2015: Aclaris Therapeutics’ Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical Trial for Seborrheic Keratosis, a Common Type of Benign Skin Tumor

Jan 27, 2015: Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Benign Skin Tumor

Jun 30, 2014: Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Seborrhea, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by ...

List of Tables

Number of Products under Development for Seborrhea, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Seborrhea - Pipeline by Aclaris Therapeutics Inc, H2 2017

Seborrhea - Pipeline by Amorepacific Corp, H2 2017

Seborrhea - Pipeline by Biomar Microbial Technologies, H2 2017

Seborrhea - Pipeline by EpiPharm AG, H2 2017

Seborrhea - Pipeline by Vyome Biosciences Pvt Ltd, H2 2017

Seborrhea - Dormant Projects, H2 2017

Seborrhea - Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Seborrhea, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by ...

List of Figures

Number of Products under Development for Seborrhea, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports